Regeneron Pharmaceuticals Inc. buy geldnutzer
Summary
This prediction ended on 19.11.20 with a price of €437.60. With a performance of -3.53%, the BUY prediction by geldnutzer finished with a loss. geldnutzer has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Regeneron Pharmaceuticals Inc. | -1.390% | -1.390% | 38.362% | 86.014% |
iShares Core DAX® | -1.215% | 4.788% | 16.604% | 15.523% |
iShares Nasdaq 100 | -1.911% | 1.109% | 19.364% | 31.093% |
iShares Nikkei 225® | -3.171% | 5.626% | 10.519% | 1.800% |
iShares S&P 500 | -1.029% | 1.792% | 20.514% | 35.443% |
According to geldnutzer what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Cons
Comments by geldnutzer for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
geldnutzer stimmt dem Sentiment von 'Sell' nicht zu
geldnutzer stimmt am 01.09.2017 dem Sell-Gesamtsentiment mit dem Kursziel 485.0$ nicht zu.
In the thread Trading Regeneron Pharmaceuticals Inc.
Stopped prediction by geldnutzer for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
23.11.20
23.11.21
24.11.21
Regeneron Pharmaceuticals Inc.
19.11.20
19.11.21
23.11.20